Pubblicazioni ultimi 4 anni del CRIMM

Koschmieder S, Mughal TI, Hasselbalch HC, et al. Myeloproliferative neoplasms and inflammation: Whether to target the malignant clone or the inflammatory process or both.


Barosi G, Tefferi A, Besses C, et al. Clinical end points for drug treatment trials in BCR-
ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).


Kroger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis.


Barbui T, Thiele J, Carobbio A, Vannucchi AM, Tefferi A. The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.


Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rationale for revision and proposed changes


Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.


Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.


Guglielmelli P, Nangalia J, Green AR, Vannucchi AM. CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum. American Journal of


Barbui T, Thiele J, Kvasnicka HM, Carobbio A, Vannucchi AM, Tefferi A. Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification.

Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia vera.


Vannucchi AM. How I treat Polycythemia vera.

Lussana F, Carobbio A, Randi ML, et al. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. British


Gupta V, Koschmieder S, Harrison CN, et al. Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis.


Rosti V, Villani L, Riboni R, et al. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.


Poletto V, Villani L, Catarsi P, et al. No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis.


Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocytthemia.


Harrison CN, Cortes JE, Cervantes F, et al. Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF).


Abstracts. 2012;120(21):801-.


Harrison CN, Vannucchi AM. Closing the gap: genetic landscape of MPN.


Amsellem S, Vannucchi AM, Le Bousse-Kerdilès MC. Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.


Barbui T, Thiele J, Carobbio A, Vannucchi AM, Tefferi A. The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.


Vannucchi AM, Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms.


Gugliotta L, Tieghi A, Tortorella G, Scalzulli PR, Ciancia R, Lunghi M, Cacciola E,


